Mid-year review: the top 10 deals of 2018
As we come to the mid-point of 2018, which mergers and acquisitions among pharmaceutical companies have been noteworthy? Two $60-billion-plus deals top the list:
Bayer’s $63-billion acquisition of Monsanto, an agrochemical and seed company, which solidifies Bayer’s move to become a pure-play life sciences company and akeda’s pending $62-billion acquisition of Shire.
SO WHICH MERGERS AND ACQUISITIONS AMONG PHARMACEUTICAL COMPANIES HAVE MADE THE MARK THUS FAR IN 2018? DCAT VALUE CHAIN INSIGHTS TAKES AN INSIDE LOOK
Two $60-billlion deals top the list. First is Bayer’s $63-billion acquisition of Monsanto, an agrochemical and seed company, the largest deal in Bayer’s history and a move to fortify its strategy of being a pure-play life-sciences company. The second is Takeda’s proposed $62-billion acquisition of Shire, coming just two years after Shire’s $32-billion acquisition of Baxalta, the biopharmaceutical company spun off from Baxter Healthcare. What other deals of import have been made thus far in 2018?
2018’s leading deals thus far
- Bayer’s $63-billion acquisition of Monsanto. Bayer completed its $63-billion acquisition of Monsanto, an agrochemical and seed company in June 2018. The deal was the largest in Bayer’s history and ended a two-year effort to acquire the company. The move fortified Bayer’s strategy of being ... ...